Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) Research & Development (2019 - 2025)

Volitionrx (VNRX) has disclosed Research & Development for 9 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 34.2% year-over-year to $2.3 million, compared with a TTM value of $10.2 million through Sep 2025, down 37.66%, and an annual FY2024 reading of $14.4 million, down 26.32% over the prior year.
  • Research & Development was $2.3 million for Q3 2025 at Volitionrx, down from $2.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.5 million in Q2 2023 and bottomed at $2.3 million in Q3 2025.
  • Average Research & Development over 5 years is $3.8 million, with a median of $3.7 million recorded in 2024.
  • The sharpest move saw Research & Development skyrocketed 66.23% in 2023, then tumbled 43.68% in 2025.
  • Year by year, Research & Development stood at $3.3 million in 2021, then surged by 43.22% to $4.7 million in 2022, then fell by 3.86% to $4.5 million in 2023, then crashed by 43.06% to $2.6 million in 2024, then fell by 11.65% to $2.3 million in 2025.
  • Business Quant data shows Research & Development for VNRX at $2.3 million in Q3 2025, $2.7 million in Q2 2025, and $2.6 million in Q1 2025.